Articles tagged with Cancer Medication
Researchers from around the world collaborated on an open-source drug-discovery project, identifying compounds to treat malaria, other parasites, and even cancer. The successful trial has sparked over a dozen new drug-development projects, bridging the gap between academia and industry.
A new chemotherapy, RCn, has shown promising results in killing cancer cells while minimizing harm to normal cells. The drug effectively shrinks tumors in mice and improves the delivery of other chemotherapy drugs.
The CU Training Program in Cancer Biology has earned a prestigious National Cancer Institute T32 grant, funding PhD-level and postdoctoral training positions. This award recognizes the program's excellence in interdisciplinary education of next-generation cancer scientists.
Researchers at Georgetown University Medical Center have found that cancer drug pazopanib decreases levels of phosphorylated Tau, a toxic brain protein linked to dementia in Alzheimer's and Parkinson's diseases. The study suggests that tau pathology may be the main culprit behind dementia in Alzheimer's disease.
Changes to HER2 testing guidelines have led to a doubling of HER2-positive breast cancers in women, resulting in additional testing and more women being labeled as HER2-positive. However, the effectiveness of targeted therapies like Herceptin is still uncertain, highlighting the need for accurate determination of HER2 status.
A novel gene therapeutic approach has been developed by WSU researchers to combat muscle wasting disease, which affects millions worldwide. The treatment, targeting a specific hormone, aims to prevent muscle loss and improve cancer patient survival rates.
Scientists at the University of Sussex are developing new cancer drugs that target DNA damage response pathways to selectively kill cancer cells. These drugs aim to maximize DNA damage or prevent its repair, leading to cancer cell death while minimizing harm to healthy tissues.
A phase II clinical study found that treating metastatic thyroid cancer patients with the BRAF mutation showed promising anti-tumor activity in a third of patients, with an overall response rate of 38%. The therapy vemurafenib joins other effective treatments for this patient population.
A new approach to discover key proteins necessary for biologics has been developed by Philip M. Kim at the University of Toronto, combining high-tech computer simulation and laboratory experiments.
A new Stanford-led analysis reveals that introducing snail-eating prawns to local water sources is the most effective way to reduce schistosomiasis prevalence, outperforming drug-only treatment by over 90%. This approach has consistently proven effective in controlling the disease globally.
A new study discovered 172 novel cancer gene-drug combinations that selectively kill cancer cells without harming healthy cells. This breakthrough expands the number of actionable mutations and provides a promising approach to personalized cancer therapy.
Two new studies estimate the economic cost of malignant and non-malignant blood disorders in Europe, with a total cost of €23 billion in 2012. Blood cancers account for a significant proportion of cancer costs, with healthcare expenses being twice as high as average across all types of cancer.
Researchers have developed a new treatment that blocks neurotransmitters to prevent nausea and vomiting caused by chemotherapy, significantly improving patient outcomes. The study found that 74% of participants experienced no nausea or vomiting when treated with olanzapine, compared to 45% on placebo.
The GW Cancer Center will train patients and healthcare providers on how to improve communications for better health, with a focus on patient health literacy and cultural sensitivity. The project aims to examine the impact of various factors such as gender, race, and income on the patient-provider relationship.
A team of researchers has obtained detailed structural information on KDM5 histone demethylase inhibitors, which could inform the design of more potent and selective anticancer drugs. The study found that these inhibitors can stop the growth of certain breast cancer cells, particularly those with specific genetic markers.
Researchers have identified a new class of molecules called selenocompounds that can kill multidrug-resistant cancer cells by blocking their defenses against chemotherapy drugs. The most active molecule worked almost four times better than the reference compound and induced cell suicide in cancer cells with similar potency.
A new technology called BiCAP maps protein complexes in breast cancer cells, providing detailed understanding of the disease at a molecular level. This allows for better understanding of how cancer cells respond to drugs and may eventually lead to new targets for therapy.
Research highlights the intertwined pathways regulating apoptosis and cellular senescence in cancer and aging. The review suggests that harnessing benefits of both processes could lead to new combination therapies, while limiting drawbacks.
A Dana-Farber Cancer Institute study found that repeated doses of an immunotherapy drug, ipilimumab, restored complete remission in some patients with relapsed blood cancers after a stem-cell transplant. The treatment reduced cancer in 59% of the patients.
A follow-up study of two US Army veterans with traumatic brain injuries (TBI) finds that while progress is slow, close personal relationships and medical care can sustain them over time. The researchers attribute the men's resilience to the importance of these factors in their recovery.
Researchers have developed an implantable device that can deliver HIV prevention drugs sustainably for up to 60 days. The transcutaneously refillable device utilizes nanochannel delivery systems to control the release of pre-exposure prophylaxis drugs, addressing a significant challenge in current treatments.
A Swiss analysis found that treating Nivolumab only to patients with positive PD-L1 tests compared to DOC or all patients with NIV is more cost-effective, with ICERs below the WTP threshold. Treating only patients with ?1% or ?10% PD-L1+ with NIV also results in improved cost-effectiveness.
A new approach shields a toxic chemotherapeutic until it reaches the tumor site, leading to greater efficacy and fewer side effects. The treatment was successful in mice with sarcoma tumors and had fewer side effects compared to traditional chemotherapy.
Site-specific conjugation technologies have enabled the development of next-generation homogeneous antibody-drug conjugates with superior stability and therapeutic index. These advancements promote the use of ADCs as a new therapeutic option for cancer patients.
Researchers have identified a possible target for a new therapy for children with primitive neuroectodermal tumors (PNETs), the most aggressive type of brain cancer in kids. The study found that inhibiting MEK activity is essential for these tumors to grow, paving the way for potential new treatment options.
Researchers at the OHSU Knight Cancer Institute have reported promising results from a Phase II clinical trial of pembrolizumab, a PD-1 antibody, in men with metastatic prostate cancer. Three out of ten participants showed significant responses to treatment, including rapid decreases in PSA levels and tumor shrinkage.
A new study has found that intensive care units provide adequate communication and family support for families of chronically ill patients, rendering palliative care unnecessary. The study revealed no difference in patient outcomes when families received additional support from palliative care specialists versus standard ICU care.
Researchers have identified a potential target for treating insulin resistance by inhibiting the protein PKD1, which limits AMPK's activity. This discovery may lead to effective treatments for obese and diabetic individuals, including lifestyle interventions such as exercise and diet modifications.
A Mayo Clinic study reveals a drug combination of TLR agonists and cyclophosphamide to effectively treat advanced and metastatic cancers in mice. The treatment promotes the destruction of cancer cells and activates immune responses without toxicity.
The new scientific statement highlights the potential of commonly used medications and nutritional supplements to cause or worsen heart failure. Healthcare providers should inform patients about all prescription and over-the-counter medications they may be taking, as well as nutritional supplements, to prevent drug-drug interactions.
A study examining cancer center advertising spending found that 20 centers accounted for 86% of the total spending. The largest advertisers were Cancer Treatment Centers of America and MD Anderson Cancer Center.
Researchers from UNC Lineberger Comprehensive Cancer Center argue that existing treatments are more effective than e-cigarettes in helping people quit smoking. They also highlight concerns about professional ethics and the need for stronger regulatory oversight.
A new analysis shows that US cancer centers increased their advertising spending by over 300% between 2005 and 2014, with for-profit organizations accounting for most of the spending. The bulk of the spending was concentrated in television ads, print media, and internet display advertisements.
Researchers created a comprehensive map of genetic and epigenetic lesions in human tumors, predicting responses to various cancer drugs. The study integrated 1,000 tumor cell lines with genetic, epigenetic, and expression alterations, validating results in 11,000 additional human samples.
A recent study has discovered a strong link between genetic mutations and sensitivity to specific drugs in patient-derived cancer cell lines. The researchers found that these cell lines harbor most of the same genetic changes found in patients' tumors, making them useful models for identifying effective treatments.
Scientists analyzed genetic mutations in patient tumors and cancer cell lines to predict which drugs will best fight various cancers. The study found that certain genetic mutations can signal whether cancer cells are sensitive or resistant to different compounds, depending on the type of tissue.
A recent study has combined data from patients, laboratory cancer cell lines, and drug sensitivity to predict how tumours are likely to respond to new drugs. The findings suggest that cancer cell lines can be used to identify the most effective treatment for individual patients, leading to improved success rates for developing personal...
A significant proportion of men with advanced prostate cancer have inherited mutations in DNA repair genes, making them eligible for precision treatments such as PARP inhibitors. Genetic testing could help identify these patients and offer targeted therapies to improve their treatment outcomes.
A phase II study evaluates the safety of palbociclib in African American patients, including those with benign ethnic neutropenia. The study aims to determine if these patients can safely use the drug, which was previously excluded due to risk of infection.
Researchers are using DNA origami to create large, two-dimensional honeycombs and tubes with precise structures. They aim to develop new medicines by exposing the immune system to DNA origami scaffolds holding virus pieces, and explore protein arrangements for sophisticated medicines and electronic devices.
A new study reveals that Argentine tango practice can significantly improve balance and reduce falls risk among cancer patients experiencing peripheral neuropathy. The dance intervention course reduced standing postural sway by 56% in just five weeks, providing a promising balance intervention for cancer survivors.
Researchers identified a new drug target, BRD9, in acute myeloid leukemia and developed a candidate drug, BI-7273. The team discovered that replacing the native bromodomain with a functionally synonymous one allowed them to prove how the drug works, providing valuable information for drug development.
The article introduces a new 'game plan' for oncologists to incorporate new therapies and approaches into clinical guidelines quickly. CancerLinQ, a web-based rapid-learning system, will provide point-of-care clinical decision support with the latest evidence-based recommendations.
Researchers have found that a combination of immunotherapy and FAK inhibitors can improve survival times in mice with pancreatic cancer. The study suggests that targeting fibrous tissue in tumors may render them more responsive to immune therapies.
Researchers found a strong five-gene signature in all patients who succumbed to the disease, regardless of their length of survival. The team also tested HXR9, which blocked HOX gene function, forcing cancer cells to close down and die, and found that combining it with cisplatin significantly increased cancer cell killing.
A new study by bioengineers at Brigham and Women's Hospital demonstrates the effectiveness of combination therapies in eliminating cancer cells. By pairing chemotherapy drug docetaxel with a targeted PI3K inhibitor, researchers achieved greater tumor inhibition and eliminated evidence of resistance.
Researchers found that increasing doses of cisplatin were associated with increased hearing loss at most tested frequencies, and high blood pressure was also linked to hearing loss in these patients. Comprehensive hearing assessments are recommended for survivors given cisplatin-based chemotherapy.
Researchers identified unique genetic signatures in four human breast cancer cell types, which can be used to tailor therapies using combinations of targeted drugs. The study found that targeting multiple driving oncogenes with lower doses reduces side effects and increases effectiveness.
Researchers develop a revolutionary approach to cancer treatment that activates two drugs within the same cell at the same time, preventing resistance in aggressive cancers. By tracking cellular signals and molecular pathways, they discovered vulnerabilities to small molecule PI3K/AKT kinase inhibitors.
Rice University scientists have streamlined the synthesis of uncialamycin, a potent anti-tumor antibiotic that can be used as part of an antibody drug conjugate. The researchers developed a scalable process for bulk production, enabling the creation of novel variations of the molecule with high potency against cancer cells.
Researchers at Johns Hopkins Medicine report a link between cancer immunotherapy drugs and rheumatologic diseases, including inflammatory arthritis. The study highlights the need for awareness among patients and clinicians about potential side effects of these drugs.
A novel combination of sorafenib and pemetrexed showed promise in a phase 1 clinical trial, with 61% of patients experiencing tumor growth delay. The therapy was particularly active in breast cancer patients, with one complete response and multiple partial responses.
A new study found that older adults who need help taking medications often have poor vision, hearing, or diagnosed conditions like stroke, diabetes, hypertension, heart attack, or cancer. The study also identified age and gender as predictors of medication assistance needs, with men and those aged 80+ being more likely to require help.
The 2016 Blavatnik National Awards recognize David Charbonneau's exoplanet discoveries, Phil Baran's natural product synthesis research, and Michael Rape's fundamental discoveries in ubiquitylation. The three Laureates receive $250,000 cash awards to support their future work.
A clinical trial found that patient navigators increased the likelihood of low-income and ethnic minority patients receiving cancer screenings. The study showed that 32% of patients connected with navigators completed at least one overdue screening, compared to 18% in the control group.
Researchers at Rice University have synthesized a new cancer-fighting compound called Thailanstatin A, which targets the spliceosome, a complex of proteins and ribonucleoproteins that regulate DNA splicing. The compound has shown promise in preclinical studies and could potentially be used to develop new therapies for cancer.
Researchers at TUM identified the molecular mechanism of thalidomide, revealing a common link between its teratogenic and anti-cancer effects. The study found that disrupting the protein complex CD147-MCT1 leads to both developmental defects and tumor cell death.
Researchers identified a small-molecule inhibitor that disrupted the recruitment of Mastermind-like protein 1 to the Notch transcription complex, inhibiting cancer cell growth and supressing tumor growth in mouse xenograft studies. This discovery represents a new paradigm for Notch-based anticancer therapeutics.
Beverages above 149 degrees Fahrenheit increase tumor risk; coffee and yerba mate safe at lower temperatures. Drinking piping hot coffee or tea increases esophageal cancer risk.
A Vanderbilt University Medical Center study found long-acting opioids significantly increase the risk of death from unintentional overdose and cardiorespiratory events. Alternative medications, such as anticonvulsants and low doses of cyclic antidepressants, may be safer options for managing moderate-to-severe chronic pain.